Deep surgical site infection rate decreased postintervention in patients undergoing arthroplasty and spine surgery<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, April 12, 2024 (HealthDay News) — Use of presurgery intranasal povidone-iodine (PVP-I) is effective for reducing the rate of surgical site infection (SSI) after joint arthroplasty and spine surgery, according to a study published online March 27 in the American Journal of Infection Control<\/em>.<\/p>\n Lisa Saidel-Odes, M.D., from Ben-Gurion University of the Negev in Beer-Sheva, Israel, and colleagues conducted a retrospective case-control study designed to reduce SSI risk after joint arthroplasty and spine surgery by reducing Staphylococcus aureus<\/em> colonization burden with PVP-I application in conjunction with skin antisepsis. The analyses included 688 adults who underwent joint arthroplasty or spine surgery during February 2018 through October 2021 (postintervention cohort) compared to a similar retrospective historical patient cohort from 2016 to 2017 (660 controls).<\/p>\n The researchers found that post-intranasal PVP-I, the eradication rate of S. aureus<\/em> nasal colonization was 39.6 percent. Patients who were positive versus negative for S. aureus<\/em> on 24-hour postsurgery nasal culture had a higher SSI rate. For all surgical procedures, the deep SSI rate per 100 operations decreased postintervention versus the historical cohort.<\/p>\n “Our study clearly shows that we can prevent surgical site infections and keep patients safer through the use of a simple presurgical nasal application of povidone-iodine in combination with standard chlorhexidine gluconate bathing,” Saidel-Odes said in a statement. “An additional application of the povidone-iodine might be needed for patients with greater nasal colonization.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n